ライフサイエンスコーパス: stimulating agent

1 ogic; normalized by treatment with erythroid-stimulating agent).

2 l gene expression response regardless of the stimulating agent.

3 ickly even in the continuous presence of the stimulating agent.

4 urkat T cell line upon treatment with T cell stimulating agents.

5 dity and mortality related to erythropoiesis stimulating agents.

6 ation, and adverse effects of erythropoiesis-stimulating agents.

7 on and trafficking, and novel erythropoiesis-stimulating agents.

8 the absence of transfusion or erythropoiesis-stimulating agents.

9 y complex (MHC) class II tetramers (TMrs) as stimulating agents.

10 eration of more focused and effective immune stimulating agents.

11 vs seven [3%]; p=0.003), and erythropoiesis-stimulating agents (26 [6%] vs four [2%]; p=0.017).

12 We showed that the RYR-stimulating agent 4-chloro-m-cresol (4CmC) induced Ca(2+

13 Erythropoiesis stimulating agent administration in sTBI is associated w

14 Erythropoiesis-stimulating agent administration to patients with cancer

15 Erythropoietin (EPO) an erythropoietic stimulating agent also exerts effects on other cell syst

16 we determined perturbations of an erythroid-stimulating agent and exercise training to examine if an

17 Erythropoiesis-stimulating agents and blood transfusion were also assoc

18 In view of the expense of erythropoiesis stimulating agents and the uncertainty of the safety of

19 e because of the therapy with erythropoiesis-stimulating agents and/or iron or despite such a therapy

20 aluated to include infection, erythropoiesis-stimulating agents, and blood transfusion.

21 ch for asymptomatic patients, erythropoiesis-stimulating agents, androgens, or immunomodulatory agent

22 away from the liberal use of erythropoiesis-stimulating agents as the main treatment for the anemia

23 proliferation profile in response to B cell-stimulating agents compared with B cells from unmanipula

24 Addition of an erythropoiesis-stimulating agent could improve response rate.

25 epatocyte cultures were treated with the PKA-stimulating agents dibutyryl-cAMP (Bt2cAMP), forskolin,

26 Erythropoiesis-stimulating agents do not seem to benefit patients with

27 xic conditions, and in responses to H(2)O(2)-stimulating agents, e.g. epidermal growth factor and lys

28 n the present study we demonstrate that cAMP-stimulating agents enhance the activity of the large-con

29 Erythropoiesis stimulating agent (ESA) administration may reduce mortal

30 onate, and creatinine; use of erythropoiesis-stimulating agent (ESA) and iron; and immunosuppressive

31 orse clinical outcomes in the erythropoiesis-stimulating agent (ESA) arm.

32 es to recommend initiating an erythropoiesis-stimulating agent (ESA) as hemoglobin (Hb) approaches, o

33 ied for the first time to the erythropoiesis stimulating agent (ESA) products, which facilitated nove

34 ginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potent

35 de, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential therapy for anem

36 Poor response to erythropoiesis-stimulating agents (ESA) is associated with morbidity an

37 of chronic kidney disease by erythropoiesis-stimulating agents (ESA) may improve survival, most stud

38 erythropoietin (EPO) analogs [erythropoiesis-stimulating agents (ESA)] are clinically used to treat a

39 estimating its typical use of erythropoiesis-stimulating agents (ESAs) and intravenous iron in hemodi

40 y, especially with the use of erythropoiesis stimulating agents (ESAs) and iron.

41 Erythropoiesis-stimulating agents (ESAs) are commonly used to treat ane

42 on alone and as an adjunct to erythropoiesis-stimulating agents (ESAs) compared with ESA alone in the

43 -placebo-controlled trials of erythropoiesis-stimulating agents (ESAs) comparing lower and higher hem

44 icans require higher doses of erythropoiesis-stimulating agents (ESAs) during dialysis to manage anem

45 The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin

46 The efficacy of erythropoietin-stimulating agents (ESAs) for improving health-related q

47 Erythropoiesis stimulating agents (ESAs) have been reported to activate

48 nges to dosing guidelines for erythropoiesis-stimulating agents (ESAs) in 2011 appear to have influen

49 rials assessing the effect of erythropoiesis-stimulating agents (ESAs) in critically ill trauma patie

50 ciency may impair response to erythropoiesis-stimulating agents (ESAs) in iron-replete patients with

51 gy recommendations for use of erythropoiesis-stimulating agents (ESAs) in patients with cancer.

52 hes to anemia management with erythropoiesis-stimulating agents (ESAs) may result in undesired patter

53 boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serious adverse even

54 The use of erythropoiesis-stimulating agents (ESAs) such as erythropoietin and dar

55 Erythropoietin-stimulating agents (ESAs) were originally designed to re

56 Erythropoiesis-stimulating agents (ESAs) were prescribed to 92% of pati

57 factor support was required; erythropoiesis-stimulating agents (ESAs) were used at the investigator'

58 dromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of appro

59 of intravenous (iv) iron and erythropoiesis-stimulating agents (ESAs).

60 and blunting the activity of erythropoiesis stimulating agents (ESAs).

61 ermine the patterns of use of erythropoiesis-stimulating agents (ESAs).

62 ith RBV dose reduction and/or erythropoiesis-stimulating agents (ESAs).

63 of potential harm from using erythropoiesis-stimulating agents (ESAs).

64 ted by cAMP analogues and the adenyl cyclase-stimulating agent forskolin.

65 The granulopoiesis-stimulating agents (GSAs) have been effectively utilized

66 tients who were not receiving erythropoiesis-stimulating agents, hemoglobin increased 0.62 +/- 1.02 g

67 g patients who were receiving erythropoiesis-stimulating agents, hemoglobin increased 1.16 +/- 1.49 g

68 of restrictions on the use of erythropoiesis-stimulating agents in cancer may impact blood availabili

69 Immunosuppressants, erythropoiesis-stimulating agents in combination with granulocyte colon

70 recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate ane

71 Trials of erythropoietin-stimulating agents in persons with kidney disease have a

72 possible beneficial effect of erythropoiesis-stimulating agents in the treatment of anemic heart fail

73 y does not support the use of erythropoiesis-stimulating agents in this subset of patients with anemi

74 odel after treatment with a variety of HIV-1 stimulating agents including PMA and TSA.

75 In response to the NADPH oxidase-stimulating agents including PMA, mBMMC and huMC produce

76 f expression in response to other cell death-stimulating agents, including ultraviolet radiation and

77 cAMP-stimulating agents increased U6 transcript levels, perha

78 ays, the development of novel erythropoiesis-stimulating agents, increasing evidence for EPO/EPOR cyt

79 This long-acting erythropoiesis-stimulating agent is as safe as conventional epoetin tre

80 0 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)

81 ologic features and dosing of erythropoiesis-stimulating agents may lead to cyclic pattern of hemoglo

82 ve control; P<0.001) and less erythropoietin-stimulating agent (median epoetin-equivalent units per w

83 reasons such as resistance to erythropoiesis-stimulating agents or cardiovascular instability.

84 nce status (KPS), exposure to erythropoiesis-stimulating agents, presence of central venous catheter

85 Erythropoietin-stimulating agent protocols are usually based on the res

86 Erythropoiesis stimulating agents remain the first-line treatment of an

87 Trials raising concerns about erythropoiesis-stimulating agents, revisions to their labeling, and cha

88 ein was increased when combined with NK-cell-stimulating agents, such as poly I:C or recombinant mous

89 to supraphysiologic levels of erythropoiesis-stimulating agent, supporting the hypothesis that hepcid

90 nd anti-D immunoglobulin, and thrombopoiesis-stimulating agents that are in early clinical developmen

91 th evidence from 17 trials of erythropoiesis-stimulating agent therapy found they offered no consiste

92 ite the near universal use of erythropoiesis-stimulating agents, there are still occasions when patie

93 plastic syndromes, relying on erythropoiesis-stimulating agents to cope with anemia, and careful moni

94 And for emerging erythropoiesis-stimulating agents, to what extent do activities paralle

95 ion, and intravenous iron and erythropoietin-stimulating agent usage as prespecified secondary outcom

96 ed strong stimuli to decrease erythropoiesis-stimulating agent use and increase intravenous iron admi

97 reduces intravenous iron and erythropoietin-stimulating agent use while maintaining hemoglobin.

98 eatment with lenalidomide and erythropoiesis-stimulating agents was shown to be an independent predic

99 oring therapeutic response to erythropoietic stimulating agents, while hyperchromic cells are an esse

100 atment options are limited to erythropoiesis-stimulating agents with or without intravenous iron ther

101 es have focused on the use of erythropoiesis-stimulating agents, with recent trials showing mixed res